A Comprehensive Review of the Analytical Development and Validation of Alprazolam in Bulk and Pharmaceutical Dosage Form

Abstract

Alprazolam is approved in 2003 by US FDA. Alprazolam is available as an extended-release tablet, a mouth dissolving tablet (a tablet that dissolves rapidly in the mouth), as well as a concentrated solution (liquid). For the treatment of severe anxiety and panic disorder, alprazolam is one of the most commonly prescribed benzodiazepines. IPUAC name of Alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a] [1, 4] benzodiazepine. The molecular formula and molecular Weight is C17H12ClFN4 and 326.75 g/mol. These articles may serve as an overview of Alprazolam with their drug profile, pharmacology, pharmacokinetics, and analytical HPLC procedures that are commonly employed in determining common provision issues. These reviews cover topics such as mobile phase, mobile phase ratio, column, retention time, flow rate, UV detector wavelength, run time, and more. Linearity, percent recovery, detection limit, and quantification limit are all validating parameters. The pharmaceutical analysis serves as an internal control for pure and pharmaceutical dosage forms, which is critical for quality assurance. The development of analytical methods has emerged as a crucial study activity.